THAR: שווי חברה לרווח נקי Tharimmune Inc

Tharimmune, Inc. (THAR) develops specific antibodies to combat tumors and autoimmune pathologies, leveraging patented technologies and a debt-free balance sheet. This daily price chart on GURU.Markets shows that the multiple is -18.40. The business operates within the US legal framework, which mitigates external political risks. However, the company faces intense pressure from pharma behemoths that possess colossal resources for expansion.

This ratio serves as a key filter during asset stress testing, allowing for the determination of the overpayment level per unit of net profit. The ratio of market capitalization to annual income reflects investor expectations, while the target P/E of Tharimmune, Inc. (THAR) demonstrates the extent to which the valuation of Tharimmune, Inc. (THAR) is subject to pressure from pharma behemoths dominating the cancer immunotherapy sector.